

AdisInsight


Written by scientists

- A database for drug research and development, disease treatment and decision making, based on trusted, scientifically-sound data
- Expertly reviewed, assessed and summarized by a team of scientists
- A single search delivers results on drugs, trials, deals and safety

New
platform

AdisInsight brings together essential scientific information on drugs in commercial development, key clinical trials, deals and safety profiles, in one easy-to-use database.

Welcome to AdisInsight

Adis Insight » Sign up / Log in 

Search: Search Advanced Search

Home • Contact Us

AdisInsight News Medwire News

17 Mar 2015
Hexetidine causes severe hypersensitivity reactions?

17 Mar 2015
Benznidazole
First report of acute generalised exanthematous pustulosis: case report

17 Mar 2015
Plerixafor
No recent reports on development identified - Registered for Stem cell mobilisation in Argentina and Brazil (SC)

Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists.

Featured Content

Adis profiles hand selected for you by our expert editorial staff

Ezetimibe/simvastatin
Developers of low-density lipoprotein (LDL) therapeutics may well be buoyed by the news this week (recently) that Merck's 18,144-patient IMPROVE-IT... [show more](#)
» [View Drug Profile](#)

NSAIDs: major cause of anaphylaxis
Nonsteroidal anti-inflammatory drugs (NSAIDs) are the drugs most frequently associated with anaphylaxis, according to the findings of an... [show more](#)
» [View Safety Report](#)

IMPROVED Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT
Merck's 18,144-patient IMPROVE-IT study has shown that the addition of ezetimibe, a drug that reduces the absorption of low-density lipoprotein (LDL)... [show more](#)
» [View Trial](#)

Whatever your involvement in the world of drug development, from a researcher to a strategist, a regulator to a healthcare provider, you will benefit from the greater perspective that AdisInsight provides.

Make better informed decisions

Gain a greater perspective of the drug landscape with a single search working across more than 200,000 drug, trial, deal and safety records

Gain a competitive advantage

Stay at the forefront of your area by adapting your research focus according to the most compelling new information

Improve work efficiency

Reduce the time taken to answer critical questions with easily digestible, consolidated scientific and commercial data

Get timely access to expert narratives

Information is assessed and consolidated from multiple sources, so you can trust the content first time around

Align efforts to improve patient care

AdisInsight makes expertly-written drug information more accessible to everyone, no matter what your background, providing a shared knowledge base to help in translating research into practice



Adis are experts in drug evaluation with more than 40 years' experience of providing trusted, independent content

Expertly-written content from across the drug lifecycle

Drugs

Access leading, evidence-based scientific and market information on drugs in commercial development worldwide. Drug and cell-based products are tracked across all therapeutic areas and throughout the entire development process, from discovery to launch.

AdisInsight drug profiles include:

- Key development milestones
- Development status and history
- Drug properties
- Chemical synopses
- Pharmacokinetics data
- Pharmacodynamics data
- Company agreements
- Trial landscape and details
- Related safety reports
- Patent information
- Related drugs
- Drug limitations
- Immunogenicity

Trials

Quickly identify the key clinical trials being performed to advance these drugs through international regulatory pathways, with coverage of both interventional and observational trials. Profiles include:

- Phase of trial and current status
- Trial purpose, focus and design
- Primary and other endpoints
- Diseases and subjects treated
- Inclusion and exclusion criteria
- Trial identifiers
- Organizations involved
- Initiation, completion and end dates
- Interventions
- Study center and investigator details
- Trial history
- Outcomes and results
- Related authors

Deals

Review concise summaries of purchases and acquisitions, joint ventures, and agreements for licensing, R&D, development, manufacturing, distribution and marketing with deal values given, where available. AdisInsight can help you to keep up with the ever-changing landscape of drug development, to identify opportunities for investment, business development and collaboration, and benchmark relative deal values and terms for your own technologies.

Safety

The most comprehensive and reliable worldwide resource for pharmacovigilance literature monitoring, AdisInsight provides fast and easy access to published adverse drug reaction (ADR) case reports, drug safety studies and regulatory news covering all drugs and therapeutic areas, updated daily. Safety records provide:

- Easy identification of serious, overdose, interaction and first published case reports
- Expert summaries of Individual Case Safety Reports (ICSRs) that comply with CIOMS II guidelines for Periodic Safety Update Reports (PSURs)
- WHO contextual adverse event data for first published case reports
- Full citation details with links to the full-text where available, to support further research
- Reports dating back to 1982

Greater perspective leads to better decision making

AdisInsight connects the world of drug development by bringing together information from each stage of the drug lifecycle into a single database.

You can retrieve highly focused results with a single search, eliminating the need to access multiple databases.

In addition to being able to search across the whole database, content within profiles is also interlinked. For example, when reading a drug profile you can see the related trials and adverse events and link through to these related records.

By connecting this information, you can see the *big picture* of a drug or disease, providing a richer context to your research and decision making and helping you to make greater discoveries.

Highlighted Feature: Trial Landscapes

Within a drug profile you can see a full trial landscape by phase and indication, helping you to predict what the lead indication/s may be, and assess how seriously other indications are being pursued

The screenshot displays the AdisInsight interface with two panels. The left panel shows the 'Drug Profile' for Ramipril, including its chemical structure, alternative names, and classification. The right panel shows the 'Trials' section for Ramipril, featuring a trial overview table and a detailed trial profile for a Phase III study.

Drug Profile: Ramipril

At a glance:

- Originator: sanofi-aventis
- Developer: AstraZeneca; King Pharmaceuticals; Monarch Pharmaceuticals; Pfizer; Sanofi
- Class: Antihypertensives; Heart failure therapies; Heterocyclic bicyclo compounds; Small molecules
- Mechanism of Action: ACE inhibitors
- Orphan Drug Status: No
- On Fast Track: No
- New Molecular Entity: Yes
- Highest Development Phases: Marketed (Cardiovascular disorders; Diabetic nephropathies; Heart failure; Hypertension); Clinical Phase Unknown (Ischaemic heart disorders); Discontinued (Kidney disorders; Type 2 diabetes mellitus)

Trial Landscape Table:

Indication	Phase 0	Phase I	Phase II	Phase III	Phase IV
Acute coronary syndromes	-	-	-	1	-
Asthenozoospermia	-	-	1	-	-
Atherosclerosis	-	-	-	2	-
Atrial fibrillation	-	-	-	1	-

Trial Profile: Phase III

At a glance:


- Drugs: Insulin; Ramipril
- Indications: Acute coronary syndromes; Myocardial infarction
- Focus: Therapeutic Use
- Acronyms: FOCUS
- Sponsors: Sanofi

Trial Overview:

>-controlled, double-blind, randomized, multicenter study of ramipril 5 and 10 mg capsules and insulin infusion in subjects with unstable coronary syndromes; will evaluate the safety and efficacy of these regimens. The primary endpoints are highly sensitive and specific for the primary endpoints.

What sets AdisInsight apart from other resources is our ...scientific expertise

Unlike our competitors, we don't just "copy and paste" or add unnecessary information in a bid to have the biggest database. Our focus is on **quality and relevance**, which is achieved by following a methodical approach to identifying, evaluating and summarizing content.



...scientific expertise

Editorial Review

Monitoring


We continuously monitor a variety of global sources to identify **new data**.



Assessing

New data is reviewed and assessed to **extract relevant information**, based on its significance and scientific merit.

Categorizing

 Detailed and consistent **indexing** is applied to support highly focused searching

Validating

Information is verified across multiple sources to **resolve discrepancies** and remove bias.

Expert Summaries

Concise narratives tell the story, using the **most compelling evidence**, and cutting out unnecessary noise.

Easy-to-use Platform

The simple search offers the fastest way to start exploring, with the most commonly used search criteria such as Drug Name, Mechanism of Action and Adverse Event, all available upfront.

Results are delivered across all content sets – drug profiles, clinical trials, safety reports and deals.

Intelligent search facets provide at-a-glance counts of results by key criteria and can be used to quickly refine your search

If you know exactly what you are looking for, you can build more detailed queries using the Advanced Search

Getting the answers you need from AdisInsight is simple, no matter how specific or broad your enquiry. The user-friendly platform is designed to help you find the information you need.

The screenshot displays the AdisInsight search results page for the query 'Exenatide'. The interface includes a search bar at the top with a dropdown menu set to 'by Drug Name' and a search button labeled 'Advanced Search'. Below the search bar, there are navigation links for 'Home' and 'Contact Us'. The main content area is divided into two sections: 'Refine Your Search' and 'Search results for Drug Name: "Exenatide"'. The 'Refine Your Search' section contains several facets with checkboxes and counts: Indication (Diabetes mellitus: 14, Metabolic disorders: 14, Type 2 diabetes mellitus: 13, Obesity: 2, Parkinson's disease: 1), Phase (Marketed: 2, Registered: 2, Phase III: 3, Phase II/III: 1, Phase II: 6), Location (USA: 9, China: 5, European Union: 5, South Korea: 5, Germany: 4), and Mechanism Of Action (Glucagon-like peptide 1 receptor agonists: 13, Glucagon-like peptide 1 stimulants: 1, Insulinotropin agonists: 1). The 'Search results' section shows a summary of 15 Drugs, 181 Trials, 45 Safety Reports, and 9 Deals. It lists three results: 'Exenatide long-acting release - AstraZeneca' (11 Mar 2015), 'Exenatide' (10 Mar 2015), and 'Exenatide sustained-release - Pepton/Yuhan Corporation' (04 Mar 2015). Each result includes details on active and inactive indications, originator, and licensor.

Start exploring the new AdisInsight today at adisinsight.springer.com

Visit adis.com/AdisInsight or email AdisInsight@springer.com to request a demo or trial.

The screenshot shows the AdisInsight homepage. At the top, there is the Adis logo and a 'Login / Register' link. Below the logo is a navigation menu with links for 'Home', 'Resources', 'Products and Services', 'About Us', and 'Contact Us'. The main content area features a 'Products & services' section with a list of links: 'Adis journals and newsletters', 'AdisInsight databases', 'New AdisInsight' (with a sub-link 'AdisInsight for drug research'), 'Pharmacovigilance solutions', and 'Custom intelligence'. To the right, there is a section titled 'Introducing the new AdisInsight platform' with the text 'Written by scientists'. This section includes a list of bullet points: 'A database for drug development and research, disease treatment and decision making, based on trusted, scientifically sound data', 'Expertly reviewed, assessed and summarized by a team of scientists', and 'A single search can deliver results on drugs, trials, safety and deals'. Below the text is a red graphic with a white triangle and dots. At the bottom, there is a paragraph explaining that AdisInsight's scientific expertise sets it apart from other information resources.